Active Surveillance for Cancer of the Prostate (ASCaP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of California, Los Angeles.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00949819
First received: July 29, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted

July 29, 2009
July 29, 2009
June 2009
Not Provided
Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables. [ Time Frame: not specified ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active intervention [ Time Frame: not specified ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Active Surveillance for Cancer of the Prostate (ASCaP)
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

This protocol is not designed as a formal clinical trial, but rather an observational protocol; no treatments and no randomization are included. Longitudinally, specimens and clinical data will be collected to provide information on the following:

  • Imaging studies of the prostate
  • Rates of curative intervention
  • Measures of tumor recurrence/progression
  • Disease specific survival
  • Overall survival
  • Clinical data to track Quality of Life
Observational
Observational Model: Ecologic or Community
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Serum, plasma, buffy coat, prostate tissue cores and urine.

Non-Probability Sample

Community sample

Prostate Cancer
Other: Observational
Serial, long term data collection
low-risk prostate cancer
Men with previously untreated, early stage prostate cancer.
Intervention: Other: Observational
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
6
Not Provided
Not Provided

Inclusion Criteria:

  1. Histologically confirmed adenocarcinoma of the prostate.
  2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  5. Patient consent has been obtained according to local Institutional Review Board .
  6. Patient is accessible and compliant for follow-up.

Exclusion Criteria:

  1. Unwillingness or inability to undergo serial prostate biopsy.
  2. Overall life expectancy less than 2 years
  3. Advanced prostate cancer
Male
30 Years to 85 Years
No
Contact: Malu Macairan (310) 794-3566 mmacairan@mednet.ucla.edu
Contact: Leonard S Marks, M.D. (310) 794-3070 lmarks@mednet.ucla.edu
United States
 
NCT00949819
ASCaP
Yes
Leonard S. Marks, M.D., UCLA
University of California, Los Angeles
Not Provided
Principal Investigator: Leonard S Marks, M.D. University of California, Los Angeles
University of California, Los Angeles
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP